Evidence map›Paper›PMID 26413328›Full record

ArticleArab journal of urology2015

Intraprostatic injection of botulinum toxin-A in patients with refractory chronic pelvic pain syndrome: The transurethral vs. transrectal approach.

Mohamed A El-Enen, Mohamed Abou-Farha, Ahmed El-Abd, Hassan El-Tatawy, Ahmed Tawfik, Shawky El-Abd, Mohamed Rashed, Mahmoud El-Sharaby

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arab journal of urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Mohamed A El-EnenUrology Department, Faculty of Medicine, Tanta University, Egypt.
Mohamed Abou-FarhaUrology Department, Faculty of Medicine, Tanta University, Egypt.
Ahmed El-AbdUrology Department, Faculty of Medicine, Tanta University, Egypt.
Hassan El-TatawyUrology Department, Faculty of Medicine, Tanta University, Egypt.
Ahmed TawfikUrology Department, Faculty of Medicine, Tanta University, Egypt.
Shawky El-AbdUrology Department, Faculty of Medicine, Tanta University, Egypt.
Mohamed RashedUrology Department, Faculty of Medicine, Tanta University, Egypt.
Mahmoud El-SharabyUrology Department, Faculty of Medicine, Tanta University, Egypt.
Tanta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the outcome of an intraprostatic injection of botulinum toxin-A (BTX-A) in men with refractory chronic prostatitis-associated chronic pelvic-pain syndrome (CP/CPPS) and to compare the efficacy of the transurethral and transrectal routes. PATIENTS AND

methodsIn an uncontrolled randomised clinical trial conducted in men with refractory CP/CPPS, the patients were classified into two groups according to the route of BTX-A injection; transurethral (group 1, 28 patients) and transrectal ultrasonography-guided (group 2, 35 patients). The chronic prostatitis symptom index (CPSI), maximum urinary flow rate (Q max) and white blood cell (WBC) count in expressed prostatic secretion (EPS) were measured before and at 3, 6 and 12 months after the injection. A significant clinical improvement (SCI, defined as a reduction of 4 points or a 25% decrease in total CPSI score) was correlated with patient age, prostate volume and symptom duration.

resultsIn group 1, the pain and quality-of-life domain scores improved, but statistically significantly only at 6 months. The voiding score improved at all follow-up visits. In group 2 there was a significant improvement in all the CPSI domain scores at all follow-up visits, except for pain, which was insignificantly improved by 12 months. The SCI ratings in groups 1 and 2 were 36%, 79% and 57%, and 49%, 89% and 74% in group 2 at the three follow-up visits, respectively. The Q max was significantly improved in both groups during the follow-up (except at 12 months in group 1). There was a significant reduction in the mean WBC count in the EPS in patients with inflammatory prostatitis. Both prostate volume and symptom duration were significantly associated with a lower SCI rating.

conclusionBTX-A is an available treatment option for patients with refractory CP/CPPS. It is more effective in patients with a small prostate and short symptom duration. The transrectal route provided better results than the transurethral route. More prospective longer term studies are needed.

Indexed as

Botulinum toxin ABTX-A, botulinum toxin type AChronic prostatitisCP/CPPS, chronic prostatitis associated with chronic pelvic pain syndromeCPSI, chronic prostatitis symptom indexEPS, expressed prostatic secretionHPF, high-power fieldNIH, National Institutes of HealthPelvic pain syndromeQmax, maximum urinary flow rateQoL, quality of lifeSCI, satisfactory clinical improvementWBC, white blood cell

Identifiers

PMID26413328
PMCPMC4561927
OpenAlexW1984981940

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.